Drug intelligence / Profile preview

carboplatin + marimastat + paclitaxel

Development stage: Unknown
Lead developer: British Biotech
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This is a combination therapy consisting of carboplatin, marimastat, and paclitaxel. Carboplatin and paclitaxel are chemotherapy drugs that destroy quickly dividing cells such as cancer cells. Marimastat is an orally bioavailable broad spectrum matrix metalloproteinase (MMP) inhibitor that prevents the degradation of the basement membrane by these proteases, thereby inhibiting tumor angiogenesis and metastasis. The combination has been studied in phase I clinical trials for patients with advanced non-small cell lung cancer.

Other names: PC + marimastatCarboTaxol + marimastat

Targets

TUBB (Tubulin (alpha and beta subunits))MMP12 (Macrophage Metalloelastase)DNA

Beyond the preview

Go deeper on carboplatin + marimastat + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + marimastat + paclitaxel.

Explore the full profile